BS_HE57E1RP
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 5.978975032851511
- age_years
- 9.597
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.720
- E2F_TARGETS+0.670
- MYC_TARGETS_V1+0.657
- G2M_CHECKPOINT+0.604
- DNA_REPAIR+0.376
- UNFOLDED_PROTEIN_RESPONSE+0.269
- SPERMATOGENESIS+0.258
- MTORC1_SIGNALING+0.192
- MITOTIC_SPINDLE+0.099
- OXIDATIVE_PHOSPHORYLATION+0.076
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.578
- INTERFERON_GAMMA_RESPONSE-0.563
- IL6_JAK_STAT3_SIGNALING-0.545
- TNFA_SIGNALING_VIA_NFKB-0.510
- INFLAMMATORY_RESPONSE-0.504
- COMPLEMENT-0.449
- NOTCH_SIGNALING-0.420
- ALLOGRAFT_REJECTION-0.417
- HEDGEHOG_SIGNALING-0.414
- HYPOXIA-0.402
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_R439VVPK | medulloblastoma | — | 0.981 |
| 2 | BS_TZVFR600 | medulloblastoma | — | 0.973 |
| 3 | BS_9NZ2D6AD | medulloblastoma | — | 0.971 |
| 4 | BS_09Z7TC35 | medulloblastoma | — | 0.958 |
| 5 | BS_GCQFGDTX | medulloblastoma | — | 0.957 |
| 6 | BS_JZRM1S3T | medulloblastoma | — | 0.956 |
| 7 | BS_W644VEVE | medulloblastoma | — | 0.952 |
| 8 | BS_M84H3KXA | medulloblastoma | — | 0.950 |
| 9 | BS_YETBN0RQ | medulloblastoma | — | 0.949 |
| 10 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.720 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.670 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.657 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.604 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.376 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.269 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.258 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.192 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.099 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.076 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.059 | Cobimetinib | — uncovered |